Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Leerink Swann raised their FY2017 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued to clients and investors on Wednesday. Leerink Swann analyst P. Matteis now anticipates that the company will post earnings of ($1.67) per share for the year, up from their prior forecast of ($2.48). Leerink Swann currently has a “Outperform” rating and a $83.00 target price on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at $0.03 EPS, Q1 2018 earnings at ($0.30) EPS, Q2 2018 earnings at ($0.29) EPS, Q3 2018 earnings at ($0.04) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.83) EPS and FY2019 earnings at $1.05 EPS.
Several other research firms have also weighed in on NBIX. Piper Jaffray Companies restated a “buy” rating and set a $76.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Jefferies Group LLC reiterated a “buy” rating and issued a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. Robert W. Baird reiterated an “outperform” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and set a $70.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, September 7th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $78.88.
Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $73.48 on Monday. Neurocrine Biosciences has a 52-week low of $37.35 and a 52-week high of $63.77. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the firm posted ($0.43) earnings per share.
In other news, insider Dimitri E. Grigoriadis sold 15,354 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total value of $844,470.00. Following the completion of the transaction, the insider now owns 123,045 shares in the company, valued at $6,767,475. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of Neurocrine Biosciences stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the transaction, the insider now owns 55,898 shares of the company’s stock, valued at approximately $3,412,013.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,346 shares of company stock worth $5,879,150. Insiders own 4.80% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. FMR LLC grew its stake in Neurocrine Biosciences by 9.8% during the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after acquiring an additional 1,180,874 shares in the last quarter. Vanguard Group Inc. grew its stake in Neurocrine Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock valued at $318,426,000 after acquiring an additional 186,329 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Neurocrine Biosciences during the second quarter valued at approximately $246,888,000. BlackRock Inc. grew its stake in Neurocrine Biosciences by 14,216.0% during the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after acquiring an additional 4,996,784 shares in the last quarter. Finally, BB Biotech AG grew its stake in Neurocrine Biosciences by 7.7% during the second quarter. BB Biotech AG now owns 3,446,552 shares of the company’s stock valued at $158,541,000 after acquiring an additional 245,000 shares in the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.